Pharmaceutical composition for resisting mycobacterium tuberculosis infection

By using C1 compounds as serine acetyltransferase inhibitors, combined with bedaquiline and clofazimin, the problems of long treatment courses and drug resistance of multidrug-resistant tuberculosis were solved, and the sensitivity to Mycobacterium tuberculosis was significantly improved. , reduces the risk of drug resistance and achieves more effective therapeutic effects.

CN118986993AActive Publication Date: 2024-11-22BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1

Patent Information

Application Number
CN202411086839.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-22
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Tuberculosis, especially multidrug-resistant tuberculosis, has long treatment courses and adverse drug reactions, which are burdened by patients, and the resistance of Mycobacterium tuberculosis to existing drugs is rapidly increasing, and new drug targets are needed to assist clinical treatment.

Method used

Develop a pharmaceutical composition for anti-Myanobacterium tuberculosis, comprising C1 compounds, bedaquiline and clofazimin, which serves as an inhibitor of serine acetyltransferase CysE, to enhance sensitivity to Myanobacterium tuberculosis, in particular When combined with bedaquiline and clofazimin, the therapeutic effect is significantly improved.

Benefits of technology

C1 alone did not affect the survival rate of M. tuberculosis, but significantly increased sensitivity to clofazimin and bedaquiline, especially when bedaquiline and clofazimin combined, significantly enhanced drug resistance. The therapeutic effect of tuberculosis reduces the risk of drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004985413220000021
    Figure BDA0004985413220000021
  • Figure BDA0004985413220000081
    Figure BDA0004985413220000081
  • Figure BDA0004985413220000091
    Figure BDA0004985413220000091
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a medicine composition for resisting mycobacterium tuberculosis infection. The invention proves that the cysE participates in reducing oxidative stress, so that the toxicity and drug resistance of M.tb are adjusted, the cysE is targeted, and particularly, the treatment of drug-resistant tuberculosis can be enhanced through the synergistic effect of the cysE, CFZ and BDQ. C1 is used as a CysE inhibitor, the survival rate of mycobacterium tuberculosis H37RvWT and delta cysE strains is not influenced when C1 is independently used for treatment, and the sensitivity of WT to BDQ is not influenced when C1 is added; however, the addition of C1 significantly increases the sensitivity of WT to CFZ as well as the sensitivity of BDQ in combination with CFZ, and the Delta cysE strain does not exhibit this enhancement. It is shown that serine acetyltransferase CysE is a target for designing the anti-mycobacterium medicine, and a CysE inhibitor C1 can effectively eliminate mycobacterium tuberculosis through the synergistic effect with CFZ and BDQ.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a pharmaceutical composition for resisting Mycobacterium tuberculosis infection. Background Art

[0002] Tuberculosis (TB) is a chronic infectious disease caused by infection with Mycobacterium tuberculosis (M.tb). According to a report released by the World Health Organization (WHO), in 2022, approximately 10.6 million people (95% UI: 9.9 million to 11.4 million) were infected with tuberculosis worldwide, and the number of multidrug-resistant tuberculosis patients increased rapidly. Among the new patients in 2022, the number of multidrug-resistant / rifampicin-resistant tuberculosis (MDR / RR-TB) was 410,000 (95% UI: 370,000 to 450,000). The incidence of tuberculosis is not optimistic (WHO. The Global Tuberculosis Report [J]. 2023.).

[0003] In 2019, WHO recommended bedaquiline (BDQ) and clofazimine (CFZ) as group A and group B drugs for the treatment of MDR / RR-TB. Studies have shown that BDQ treatment of M.tb and extensively drug-resistant tuberculosis (XDR-TB) helps improve the negative conversion rate of sputum smears and sputum cultures, has a high success rate, good safety, and improves the absorption of imaging lesions in patients (KOIRALA S, BORISOV S, DANILA E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort [J]. Pulmonology, 2021, 27 (5): 403-412.). Treatment regimens containing CFZ can also significantly shorten the treatment time required to cure drug-sensitive tuberculosis, significantly improve the sputum negative conversion rate and lesion absorption rate of XDR-TB patients (DUAN H, CHEN X, LI Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial [J]. Clin Microbiol Infect, 2019, 25 (2): 190-195.), and reduce adverse reactions in patients, with good safety and tolerability (Wan Qiu, Yang Fuping, Tang Lixin. Efficacy and safety analysis of combination regimens containing clofazimine in the treatment of multidrug-resistant tuberculosis [J / CD]. Chinese Journal of Lung Diseases (Electronic Edition), 2023, 16 (2): 275-277.). Although new drugs such as BDQ, CFZ, and pretomanid (PA-824) have been developed, the treatment of tuberculosis, especially multidrug-resistant tuberculosis, still takes several months and has adverse drug reactions, which undoubtedly increases the burden on patients. Tuberculosis resistance poses a major threat to human health around the world, and it is urgent to identify new drug targets to assist in the treatment of clinical drug-resistant tuberculosis.

[0004] Acetyltransferases play crucial roles in biological processes by modifying a variety of substrates. There are 47 acetyltransferase-encoding genes in the Mycobacterium tuberculosis genome. Some of these enzymes are associated with the virulence of M.tb. However, their role in the virulence of M.tb is still unclear. To systematically investigate the role of acetyltransferases in M.tb, an acetyltransferase mutant library was constructed using CRISPR-assisted genome editing and screened for genes essential for mouse infection. cysE, encoding a serine acetyltransferase, was confirmed to be required for the virulence of M.tb in mice and its replication in macrophages. Further experiments showed that mutation of cysE or inhibition of cysE by small molecule chemicals increased the sensitivity of M.tb to CFZ treatment.

[0005] Compound 1 (C1) was identified as a potential inhibitor of the enzyme CysE in M.tb (Gupta S, Gupta V. in-silico Homology modeling, structural insights and screening for selective inhibitors of mycobacterial CysE[J]. Journal of biomolecular structure & dynamics, 2021, 39(5): 1547-60.). So far, there have been no reports of C1 being used for the treatment of tuberculosis at home and abroad. In order to avoid the emergence of drug resistance during drug treatment, a combination of anti-tuberculosis drugs is often used in clinical practice to improve the therapeutic efficacy and reduce the occurrence of drug resistance. Summary of the invention

[0006] The present invention found that the use of C1 alone did not affect the survival rate of Mycobacterium tuberculosis, and the addition of C1 significantly increased the sensitivity of Mycobacterium tuberculosis H37Rv wild-type strain to CFZ and the sensitivity of BDQ and CFZ combination, while the ΔcysE strain did not show such an enhancement effect. Based on this, the present invention was completed.

[0007] In a first aspect, the present invention provides a pharmaceutical composition for resisting Mycobacterium tuberculosis infection, the pharmaceutical composition comprising a C1 compound, bedaquiline and clofazimine, wherein the molecular formula of the C1 compound is: 21 H 21 CIN6O3S, structural formula shown in formula 1;

[0008] Compound 1(C1)

[0009]

[0010] The pharmaceutical composition has at least one of the following effects:

[0011] a) inhibiting the activity of Mycobacterium tuberculosis;

[0012] b) Anti-Mycobacterium tuberculosis infection;

[0013] c) Prevention and / or treatment of diseases caused by Mycobacterium tuberculosis.

[0014] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.

[0015] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.

[0016] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

[0017] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.

[0018] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.

[0019] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.

[0020] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.

[0021] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.

[0022] Furthermore, the pharmaceutical composition may also contain other active ingredients for resisting Mycobacterium tuberculosis infection.

[0023] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.

[0024] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.

[0025] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.

[0026] Furthermore, the tablets may widely use various carriers known in the art, including one or more of diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption enhancers and / or lubricants.

[0027] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose and / or aluminum silicate.

[0028] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinyl pyrrolidone.

[0029] Furthermore, the disintegrant includes, but is not limited to, one or more of dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.

[0030] Furthermore, the disintegration inhibitor includes but is not limited to sucrose, tristearin, cocoa butter and / or hydrogenated oil.

[0031] Furthermore, the absorption enhancer includes but is not limited to one or more of quaternary ammonium salts and / or sodium lauryl sulfate.

[0032] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin and / or polyethylene glycol.

[0033] Furthermore, the tablets can be further made into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets and multi-layer tablets.

[0034] Furthermore, the injectable preparation includes, but is not limited to, one or more of a solution, an emulsion, a lyophilized powder injection and / or a suspension.

[0035] Furthermore, the injectable preparation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol and / or polyoxyethylene sorbitan fatty acid esters.

[0036] Furthermore, in order to prepare an isotonic injection solution, the injection preparation may be added with an appropriate amount of one or more of sodium chloride, glucose, glycerol, conventional cosolvents, buffers and / or pH regulators.

[0037] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.

[0038] Furthermore, the pharmaceutical composition can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.

[0039] In a second aspect, the present invention provides a C1 compound for use as a synergist for the combined anti-Mycobacterium tuberculosis infection effect of bedaquiline and clofazimine. When the C1 compound is used in combination with bedaquiline and clofazimine, the C1 compound can enhance the anti-Mycobacterium tuberculosis infection activity of bedaquiline and clofazimine; wherein the structural formula of the C1 compound is shown in Formula 1.

[0040] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.

[0041] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.

[0042] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

[0043] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.

[0044] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.

[0045] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.

[0046] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.

[0047] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.

[0048] In a third aspect, the present invention provides an application of a C1 compound, bedaquiline and clofazimine in combination for preparing an anti-Mycobacterium tuberculosis infection pharmaceutical composition, wherein the C1 compound, bedaquiline and clofazimine are used in combination to exert an anti-Mycobacterium tuberculosis infection effect, and the C1 compound can enhance the anti-Mycobacterium tuberculosis infection activity of bedaquiline and clofazimine in combination; wherein the structural formula of the C1 compound is shown in Formula 1.

[0049] Furthermore, the Mycobacterium tuberculosis includes clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.

[0050] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, extrapulmonary infection, and pulmonary infection.

[0051] Furthermore, the diseases caused by Mycobacterium tuberculosis include but are not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

[0052] Furthermore, the drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.

[0053] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis, etc.

[0054] Furthermore, the extrapulmonary tuberculosis includes but is not limited to lymph node tuberculosis, intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.

[0055] Furthermore, the Mycobacterium tuberculosis includes multidrug-resistant Mycobacterium tuberculosis and extensively drug-resistant Mycobacterium tuberculosis.

[0056] Furthermore, the Mycobacterium tuberculosis includes Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium cannabinum and Mycobacterium microti.

[0057] Furthermore, the pharmaceutical composition may also contain other active ingredients for resisting Mycobacterium tuberculosis infection.

[0058] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.

[0059] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.

[0060] Furthermore, the preparation can be one or more of a conventional preparation, a sustained-release preparation, a controlled-release preparation and / or various microparticle delivery systems.

[0061] Furthermore, the tablets may widely use various carriers known in the art, including one or more of diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption enhancers and / or lubricants.

[0062] Furthermore, the diluent and absorbent include, but are not limited to, one or more of starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose and / or aluminum silicate.

[0063] Furthermore, the wetting agent and adhesive include, but are not limited to, one or more of water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and / or polyvinyl pyrrolidone.

[0064] Furthermore, the disintegrant includes, but is not limited to, one or more of dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose and / or ethyl cellulose.

[0065] Furthermore, the disintegration inhibitor includes but is not limited to sucrose, tristearin, cocoa butter and / or hydrogenated oil.

[0066] Furthermore, the absorption enhancer includes but is not limited to one or more of quaternary ammonium salts and / or sodium lauryl sulfate.

[0067] Furthermore, the lubricant includes, but is not limited to, one or more of talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin and / or polyethylene glycol.

[0068] Furthermore, the tablets can be further made into coated tablets, including sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets and multi-layer tablets.

[0069] Furthermore, the injectable preparation includes, but is not limited to, one or more of a solution, an emulsion, a lyophilized powder injection and / or a suspension.

[0070] Furthermore, the injectable preparation may use all diluents commonly used in the art, including but not limited to one or more of water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol and / or polyoxyethylene sorbitan fatty acid esters.

[0071] Furthermore, in order to prepare an isotonic injection solution, the injection preparation may be added with an appropriate amount of one or more of sodium chloride, glucose, glycerol, conventional cosolvents, buffers and / or pH regulators.

[0072] Furthermore, the various preparations may also add colorants, preservatives, spices, flavoring agents, sweeteners or other materials to the pharmaceutical preparations as needed.

[0073] Furthermore, the pharmaceutical composition can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.

[0074] Beneficial Effects

[0075] This application demonstrates that cysE is involved in alleviating oxidative stress, thereby regulating the virulence and drug resistance of M.tb. Targeting cysE, especially through synergy with CFZ and BDQ, can enhance the treatment of drug-resistant tuberculosis. C1 is a CysE inhibitor, and treatment with C1 alone does not affect the H of Mycobacterium tuberculosis. 37 The survival rates of RvWT and ΔcysE strains were significantly lower than those of RvWT and ΔcysE strains, and the addition of C1 did not affect the sensitivity of WT to BDQ; however, the addition of C1 significantly increased the sensitivity of WT to CFZ and the combination of BDQ and CFZ, and the ΔcysE strain did not show such an enhancement. This indicates that serine acetyltransferase CysE is a target for designing anti-mycobacterial drugs, and the CysE inhibitor C1 can synergize with CFZ and BDQ to effectively eliminate Mycobacterium tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] Figure 1 .Next-generation sequencing results of the ΔcysE knockout strain.

[0077] Figure 2 .IC50 curve of anti-tuberculosis drugs against Mycobacterium tuberculosis. ((A) Bedaquiline; (B) Clofazimine.)

[0078] Figure 3 . In vitro bactericidal ability test of anti-tuberculosis drugs. (On day 0, bedaquiline, clofazimine, or bedaquiline and clofazimine were used together for 3 days (A) and 7 days (B), all using 20×MIC drug concentrations. At the indicated times, aliquots were taken out, serially diluted, and CFU / mL was determined to calculate the survival rate. The results represent the mean ± SD of three independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test, *P<0.05, **P<0.01, and ***P<0.001.)

[0079] Figure 4. ROS levels in Mycobacterium tuberculosis after different treatments. (MFI, mean fluorescence intensity; UT represents untreated control group; 100×MIC of BDQ and CFZ treatment; statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.)

[0080] Figure 5 . Detection of ATP content in Mycobacterium tuberculosis. (UT represents untreated control group; BDQ and CFZ treatment at 100×MIC; statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test, *P<0.05, **P<0.01 and ***P<0.001.)

[0081] Figure 6 .Intracellular killing assay in THP-1 macrophages. (A) CCK8 cell viability assay. Data show the mean ± SD of five samples and are representative of at least two independent experiments. The horizontal dashed line indicates cell viability = 75%. (B) Killing of the indicated strains induced by treatment with 20×MIC BDQ, CFZ, and BDQ+CFZ over 48 h. 5×10 cells / well were infected with the indicated strains at an MOI of 10. 5 THP-1 cells were used to determine bacterial survival. Survival was calculated using CFU before drug treatment (6 h) as a control, and UT represents untreated control. Data show the mean ± SD of five samples and are representative of at least two independent experiments. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test, *P < 0.05, **P < 0.01, and ****P < 0.0001. )

[0082] Figure 7 Serine acetyltransferase inhibitors can effectively eliminate Mycobacterium tuberculosis. ((A) Chemical structures and chemical formulas of the compounds. (B and C) Early logarithmic phase cultures of the WT strain (B) and the ΔcysE strain (C) were treated with or without 20×MIC CFZ, 20×MIC BDQ+CFZ, and 0.5 mg / mL C1 on day 0 for 7 days, and then CFU were counted. UT stands for untreated control. Data represent the mean ± SD of four biological replicates and are representative of at least two independent experiments. Statistical analysis was performed using unpaired two-tailed t-test, ***P<0.001 and ****P<0.0001.) DETAILED DESCRIPTION

[0083] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0084] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0085] the term

[0086] Non-homologous end joining (NHEJ) repair is also one of the main repair pathways for intracellular DSBs. Compared with homologous recombination (HR), NHEJ is more likely to cause insertion and / or deletion mutations at the DSB site and produce frameshift mutations that damage the target gene. However, compared with the repair pathways of eukaryotic organisms, most bacteria lack an endogenous NHEJ repair system and mainly repair DSBs through the HR pathway. At present, a few bacteria such as mycobacteria, Pseudomonas aeruginosa and Bacillus subtilis have been found to have NHEJ repair pathways.

[0087] Example

[0088] The molecular formula of C1 compound is: 21 H 21 CIN6O3S; the structural formula is as follows:

[0089] Compound 1(C1)

[0090]

[0091] Example 1 Mycobacterium tuberculosis culture

[0092] This application uses Mycobacterium tuberculosis strain H 37 RvWT, ΔcysE knockout strain and ΔcysE::cysE complemented strain.

[0093] Mycobacterium tuberculosis strains were cultured in liquid form in Middlebrook 7H9 medium (BD Biosciences) supplemented with 10% OADC and 0.2% glycerol and 0.05% Tween-80, and in solid form in 7H10 agar (BD Biosciences) supplemented with 10% OADC and 0.5% glycerol. When necessary, antibiotics and small molecules were used at the following concentrations: kanamycin (25 μg / ml), hygromycin (50 μg / ml), bleomycin (50 μg / ml) and anhydrotetracycline (ATc) (50 ng / ml).

[0094] The bacterial strains and plasmids used in this application are shown in Table 1; the oligonucleotides used in this application are shown in Table 2.

[0095] Table 1 Bacterial strains and plasmids used in this application

[0096]

[0097] Note: [1] Yan MY,Li SS,Ding XY,et al.ACRISPR-AssistedNonhomologous End-Joining Strategy for Efficient Genome Editing in Mycobacterium tuberculosis[J].mBio,2020,11(1):02364-19.

[0098] Table 2 Oligonucleotides used in this application

[0099]

[0100]

[0101] Example 2 Construction of Mycobacterium tuberculosis gene knockout and complementation strains

[0102] 2.1M.tb competent cells

[0103] Prepare M.tb competent cells containing helper plasmids and with high editing efficiency (Goude R, Roberts DM, Parish T. Electroporation of mycobacteria[J]. Methods in molecular biology(Clifton, NJ), 2015, 1285(117-30.DOI:10.1007 / 978-1-4939-2450-9_7).

[0104] 2.2 CysE large fragment gene knockout mutant

[0105] CRISPR-NHEJ gene editing technology was used to construct a large cysE gene knockout mutant. Briefly, the synthetic pYC1876 plasmid containing dual sgRNAs was transformed into H 37 Rv::NHEJ competent cells, and recombinants were selected on 7H10+OADC plates containing 50 μg / ml bleomycin and 25 μg / ml kanamycin. Successfully constructed mutants were screened by PCR using specific primers (cysE knockout verification), and then the NHEJ auxiliary plasmid pYC1759 and the pYC1876 plasmid containing double sgRNA were lost by negative selection by inoculating them on 7H10 agar plates containing 2% sucrose to obtain ΔcysE strains.

[0106] 2.3ΔcysE::cysE strain

[0107] For complementation experiments, the pYC874-L5 vector was digested at NotI and XbaI sites, and the full-length cysE gene (Rv2335) and a 500 bp region upstream of the coding region were amplified from M.tb genomic DNA using specific primers (500 bp-cysE fragment). The full-length hsp60 (hsp60 fragment) was amplified from pMV261, and the digested pYC874-L5 and hsp60 and 500 bp-cysE were seamlessly ligated to generate the pYC874-cysE complementing plasmid, which was electroporated into the ΔcysE strain to obtain the ΔcysE::cysE strain.

[0108] 2.4 Results

[0109] The next generation sequencing results of the ΔcysE knockout strain (such as Figure 1 shown).

[0110] Example 3 Mycobacterium tuberculosis MIC determination

[0111] 3.1 Test steps

[0112] The minimum inhibitory concentration (MIC) of the drugs against various M. tb strains was determined using the broth microdilution technique.

[0113] Various anti-tuberculosis drugs were serially diluted 2-fold in a 96-well plate, and 100 μL M.tb culture (OD 600 ~0.05), incubate. Record OD 600 IC50 curve was drawn. On the 7th day, 20 μl of Lamar blue and 50 μl of 5% Tween-80 were added to the wells in sequence. MIC detection.

[0114] 3.2 Test results

[0115] The Alamar Blue method was used to detect the effect of ΔcysE on the MIC of various anti-tuberculosis drugs. 37 The Rv WT, ΔcysE, and ΔcysE::cysE strains had similar MICs to all tested anti-TB drugs (isoniazid, INH; rifampicin, RIF; levofloxacin, LFX; amikacin, AMK; ethambutol, EMB; Q203; linezolid, LZD; delamanid, DLM) except clofazimine (CFZ) and bedaquiline (BDQ) (as shown in Table 3 ).

[0116] When exposed to CFZ and BDQ, the MIC of ΔcysE was approximately 1 / 2 of that of the wild-type strain WT, while the MIC of the ΔcysE::cysE complemented strain was similar to that of the wild-type strain WT.

[0117] The IC50 curve was further drawn and found to be similar to the MIC result trend (e.g. Figure 2 MIC detection showed that the knockout strain showed higher sensitivity to BDQ and CFZ compared with the wild-type strain and the complemented strain.

[0118] Table 3 Activity of compounds against strains (MIC 90 )(μg / mL)

[0119]

[0120] Example 4 Determination of the in vitro bactericidal ability of drugs against Mycobacterium tuberculosis

[0121] 4.1 Test steps

[0122] Mycobacterium tuberculosis H 37 Rv WT, ΔcysE and ΔcysE::cysE strains were grown in 7H9+OADC to mid-logarithmic phase (OD 600 ~0.8).

[0123] The bacteria were collected by centrifugation and inoculated into 7H9+OADC medium containing or not containing 20×MIC of various drugs (OD 600 ~0.04). Centrifuge at 3 and 7 days after treatment, wash the cells and spread them on 7H10+OADC agar plates. Count CFU after culture.

[0124] The CFU of the group without drug treatment was used as the control group to calculate the survival rate.

[0125] The effect of cysE on the susceptibility of M. tuberculosis to BDQ and CFZ was further determined by killing kinetics.

[0126] 4.2 Test results

[0127] Consistent with the MIC results, the survival rate of ΔcysE was significantly reduced after 7 days of CFZ exposure compared with WT (Fig. Figure 3 B). Combined treatment with BDQ and CFZ resulted in a further reduction in the survival rate of ΔcysE. Combined treatment with BDQ and CFZ killed more than 99.9% of M.tb for 7 days. Treatment with BDQ and CFZ alone for 7 days killed only about 99.9% and 99% of M.tb, respectively. After 7 days of combined treatment with BDQ and CFZ, ΔcysE resulted in more than 10 5 times the damage (such as Figure 3 B).

[0128] Example 5 Detection of ROS in Mycobacterium tuberculosis by flow cytometry

[0129] 5.1 Test steps

[0130] ROS accumulation in M. tuberculosis was measured using a ROS-sensitive fluorescent dye.

[0131] Carboxy-H2DCFDA (final concentration 10 μM) was added to the cultures for detection of total ROS within tuberculosis bacteria. Cultures lacking the fluorescent dye were included as controls for autofluorescence (little was detected).

[0132] Fluorescence intensity of bacteria was measured using fluorescence-based flow cytometry 1.5 h after CFZ or BDQ treatment. Samples (200 μL) collected at different times were subsequently analyzed by flow cytometry. A total of 100,000 bacteria per sample were analyzed at a rate of 35 μL / min to determine the fluorescence value. The detection parameters were 20 mV laser power and 533 / 30 nm bandpass filter.

[0133] 5.2 Test results

[0134] CFZ treatment increased the ROS level of M. tuberculosis, thereby killing M.tb.

[0135] cysE affects ROS levels in M.tb, thereby affecting resistance to CFZ. ROS levels in M.tb cultures with or without CFZ or BDQ treatment were quantified by flow cytometry. It was found that treatment with CFZ, but not BDQ, significantly increased ROS levels in M.tb. ΔcysE significantly increased ROS levels after CFZ treatment, indicating that the cysE mutation may enhance bactericidal activity by increasing ROS levels under CFZ treatment. In addition, combined treatment with BDQ and CFZ enhanced ROS production by CFZ, leading to rapid killing of M.tb.

[0136] Example 6 Detection of ATP Levels in Mycobacterium tuberculosis

[0137] 6.1 Test steps

[0138] The assay was performed according to the instructions of the ATP assay kit (S0026B).

[0139] H 37 RvWT, ΔcysE, and ΔcysE::cysE strains were adjusted to OD 600 ~0.08, and then add the drug 1:1 to the desired concentration. After incubation for different times, mix the samples with 200 μL ATP detection lysate to lyse the bacteria. Centrifuge the samples, transfer the supernatant to a new tube, and mix with an equal volume of ATP detection reagent. Measure luminescence using an EnVision multi-mode microplate reader.

[0140] 6.2 Test results

[0141] BDQ targets AtpE, which is involved in ATP synthesis, so treatment with BDQ can reduce ATP levels in mycobacteria, which is one of the main mechanisms of BDQ bactericidal activity. To determine whether drug treatment changes ATP levels, ATP was quantified in cells treated with or without drug.

[0142] BDQ treatment for 48 h significantly reduced ATP levels in M. tuberculosis, whereas CFZ treatment did not affect ATP levels. Deficiency of cysE reduced ATP levels during the initial phase of BDQ treatment (3 and 24 h), but did not continue to reduce ATP levels after long-term treatment (48 h). Figure 5 ), which shows that the cysE mutation does not enhance the bactericidal effect of BDQ against Mycobacterium tuberculosis.

[0143] Example 7: Bactericidal Experiment Verification in THP-1 Macrophages

[0144] 7.1 Test steps

[0145] THP-1 cells were collected at 5×10 4 The cells were seeded into a 96-well plate at a density of 100 μL / well, and 20×MIC of the drug was added to the wells. The cell viability was determined according to the cell counting kit-8 (CCK-8) assay.

[0146] To detect the effect of cysE on the intracellular bactericidal activity of M.tb after phagocytosis by macrophages, H 37 Rv WT, ΔcysE and ΔcysE::cysE strains were cultured in 7H9+OADC liquid medium without antibiotics until the OD value of the stable phase was 600 ~0.8, transferred to fresh culture medium at 1:10, and cultured again until the stable OD 600~0.8 and then used in cell invasion experiments.

[0147] Each strain was resuspended in RPMI 1640, centrifuged, the waste liquid was discarded, and a single cell suspension was obtained by resuspending and ultrasonication. THP-1 macrophages were infected with an MOI of 1:10 (cell: bacteria) and cultured. After infection, the culture medium was removed, washed, and the cells were lysed. Then, the lysate was diluted in multiples and spread on 7H10+OADC agar plates. The cells in other parallel wells continued to be incubated in their wells with RPMI 1640 containing different drugs at 20×MIC, and the lysed cells were diluted in multiples and spread on 7H10+OADC agar plates. CFU colony counts were performed after 20 days of culture.

[0148] 7.2 Test results

[0149] The intracellular bactericidal activity was verified at the THP-1 macrophage level.

[0150] The results showed that BDQ and CFZ treatment of cells for 2 days had no significant effect on cell survival (e.g. Figure 6 As shown in A), for intracellular survival, mutations in cysE all resulted in stronger killing, and combined treatment with BDQ and CFZ resulted in further killing by ΔcysE (as shown in Figure 6 B).

[0151] Example 8 CFU Determination of CysE Small Molecule Inhibitors and Drug Combinations of Mycobacterium tuberculosis

[0152] 8.1 Test steps

[0153] Mycobacterium tuberculosis H 37 RvWT and ΔcysE strains were grown in 7H9+OADC to the mid-logarithmic phase (OD 600 The bacteria were collected by centrifugation and inoculated into 7H9+OADC medium containing or not containing 20×MIC of various drugs (OD 600 ~0.04). Centrifuge on day 7 after treatment, wash the cells and spread on 7H10+OADC agar plates. Count CFU after 3 weeks of culture.

[0154] 8.2 Test results

[0155] Compound 1 (C1) (such as Figure 7A) has been identified as a potential inhibitor of the enzyme CysE in Mycobacterium tuberculosis (Gupta S, Gupta V. in-silico Homology modeling, structural insights and screening for selective inhibitors of mycobacterial CysE [J]. Journal of biomolecular structure & dynamics, 2021, 39 (5): 1547-60.). The synergistic effect of C1 on the bactericidal activity of CFZ and BDQ was evaluated, thereby identifying CysE as an important target for adjuvant tuberculosis treatment.

[0156] Treatment with C1 alone did not affect the 37 The survival rate of RvWT and ΔcysE strains (e.g. Figure 7 B and 7C), and the addition of C1 did not affect the sensitivity of WT to BDQ; however, the addition of C1 significantly increased the sensitivity of WT to CFZ and the sensitivity of the combination of BDQ and CFZ (as shown in Figure 7 B), and the ΔcysE strain did not show this enhancement effect (as shown in Figure 7 C). This suggests that the CysE inhibitor C1 can synergize with CFZ and BDQ to effectively eliminate Mycobacterium tuberculosis.

Claims

1. A pharmaceutical composition for preventing Mycobacterium tuberculosis infection, comprising a C1 compound, bedaquiline and clofazimine, wherein the molecular formula of the C1 compound is: 21 H 21 CIN 6 O 3 S, the structural formula is shown in Formula 1; The pharmaceutical composition has at least one of the following effects: a) inhibiting the activity of Mycobacterium tuberculosis; b) Anti-Mycobacterium tuberculosis infection; c) Prevention and / or treatment of diseases caused by Mycobacterium tuberculosis.

2. A use of a C1 compound, bedaquiline and clofazimine in combination in the preparation of a pharmaceutical composition for the treatment of Mycobacterium tuberculosis infection, wherein the C1 compound, bedaquiline and clofazimine are used in combination to exert an anti-Mycobacterium tuberculosis infection effect, and the C1 compound can enhance the anti-Mycobacterium tuberculosis infection activity of bedaquiline and clofazimine; in, The structural formula of the C1 compound is shown in Formula 1.

3. A use of a C1 compound as a synergist of the anti-Mycobacterium tuberculosis infection effect of bedaquiline and clofazimine in combination, wherein when the C1 compound is used in combination with bedaquiline and clofazimine, the C1 compound can enhance the anti-Mycobacterium tuberculosis infection activity of bedaquiline and clofazimine; in, The structural formula of the C1 compound is shown in Formula 1.

4. The pharmaceutical composition according to claim 1 or 2, further comprising other active ingredients against Mycobacterium tuberculosis infection.

5. The pharmaceutical composition as claimed in claim 1 or 2, further comprising one or more pharmaceutically acceptable carriers.

6. The pharmaceutical composition as claimed in claim 1 or 2 can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution, injection preparation or aerosol; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.

7. The pharmaceutical composition as claimed in claim 1 or 2 can be introduced into the body by physical or chemical methods, such as intramuscularly, intradermally, subcutaneously or intravenously.

8. The Mycobacterium tuberculosis infection according to any one of claims 1 to 3, include: Primary infection, secondary infection, extrapulmonary infection, pulmonary infection.

9. The Mycobacterium tuberculosis according to any one of claims 1 to 3, comprising clinical isolates of Mycobacterium tuberculosis, standard strains of Mycobacterium tuberculosis and / or Mycobacterium tuberculosis carried by patients infected with Mycobacterium tuberculosis.

10. The disease caused by Mycobacterium tuberculosis according to any one of claims 1 to 3, including but not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

Citation Information

Patent Citations

  • Application of 5-iodine tuberculin in preparation of medicine for inhibiting mycobacterium tuberculosis

    CN116421612A

  • Application of KY1220 in preparation of medicine for inhibiting mycobacterium tuberculosis

    CN116650478A

Cited By

  • Combined synergistic pharmaceutical composition for resisting mycobacterial infection

    CN119564683A

  • A synergistic pharmaceutical composition for resisting mycobacterial infection

    CN119564683B